블로그

• [FDA, 200616] 마일로타그, CD33+ 급성 골수성 백혈병 허가 . - 얘는 mAB On June 16, 2020, the Food and Drug Administration extended the indication of gemtuzumab ozogamicin (MYLOTARG, Wyeth Pharmaceuticals LLC) for newly-diagnosed CD33-positive acute myeloid leukemia (AML) blog.naver.com · 2020.06.30